HIKAL LTD.

Hikal Ltd has informed its members, particularly those without registered email addresses, about the availability of its Annual Report for the Financial Year 2025-26. The company is providing a weblink and the exact path on its website where the complete report can be accessed, in compliance with SEBI (LODR) Regulations, 2015. This communication also serves as a reminder for members to update their KYC details and dematerialize physical securities, with specific forms and SEBI circulars available on the company's investor relations portal. The 38th Annual General Meeting is scheduled for September 23, 2026.

Hikal Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as required by SEBI regulations. The report, which forms part of the Annual Report, details the company's ESG performance on a consolidated basis. Key disclosures include its business activities in pharmaceuticals, animal health, crop protection, and specialty chemicals, contributing 100% to turnover. The company operates 6 manufacturing facilities and 3 R&T centers in India, with international offices in Japan, USA, and representation in Europe. Exports constitute 69% of total turnover. The report also outlines employee details, including a workforce of 2077 employees and 1056 workers, with specific data on differently-abled personnel. Sustain Right provided reasonable assurance for the BRSR Core assessment.

Hikal Ltd has released its Annual Report for the financial year 2025-26, along with the notice for its 38th Annual General Meeting (AGM). The report highlights the company's focus on innovation and sustainability, emphasizing advancements in its Pharmaceuticals, Crop Protection, and Animal Health businesses. Key developments include strengthening the CDMO pipeline, operationalizing a High-Potency API (HPAPI) laboratory, and commissioning a Kilo Lab to accelerate scale-up. The company also reinforced quality, compliance, and manufacturing excellence while embedding sustainability across operations. The report details strategic reviews, financial performance, risk management, and ESG initiatives, underscoring Hikal's commitment to creating long-term value for stakeholders.

Hikal Ltd has issued a notice for its 38th Annual General Meeting (AGM) to be held on Wednesday, September 23, 2026, at 11:30 a.m. IST via Video Conferencing/Other Audio-Visual Means. The agenda includes the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026. Key proposals also involve confirming an interim dividend of ₹0.20 and declaring a final dividend of ₹0.40 per equity share, totaling ₹0.60 for FY 2025-26. Additionally, the AGM will address the re-appointment of a director retiring by rotation and the appointment of Mr. Sameer Hiremath as Chairman and Managing Director for a five-year term starting October 1, 2026, along with fixing his remuneration.

Hikal Ltd announced its Board of Directors has recommended a final dividend of ₹0.40 per equity share for the Financial Year ended March 31, 2026. This dividend is subject to shareholder approval at the upcoming 38th Annual General Meeting (AGM) on September 23, 2026. The record date for determining eligibility is September 4, 2026. The company also informed shareholders about the tax implications of dividend income as per the Income Tax Act, 2025, detailing Tax Deducted at Source (TDS) provisions for resident and non-resident shareholders. Shareholders are advised to update their bank details for timely credit.

Hikal Ltd announced that its Board of Directors has decided to hold the 38th Annual General Meeting (AGM) on September 23, 2026. The AGM will be conducted via Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The company has fixed September 4, 2026, as the Record Date to determine eligibility for the Final Dividend for the Financial Year 2025-26. If declared at the AGM, the Final Dividend will be paid on or before October 23, 2026.

Hikal Ltd announced the appointment of Mr. Sameer Hiremath as Chairman and Managing Director (CMD) for a term of five years, effective October 1, 2026, to September 30, 2031. This appointment is subject to shareholder approval at the upcoming Annual General Meeting (AGM). Mr. Hiremath, currently Vice Chairman and Managing Director, brings nearly three decades of experience and deep institutional knowledge to the role. He holds degrees in Petrochemical Engineering, an MBA, and an MS in Information Technology from Boston University. The board's decision was based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee. Mr. Hiremath is not debarred from holding a director's office.

Hikal Ltd has announced the record date for determining eligibility for the final dividend for the Financial Year 2025-26. The 38th Annual General Meeting (AGM) is scheduled for September 23, 2026, where shareholders will vote on the dividend declaration. The record date has been fixed as September 04, 2026. If declared, the dividend will be paid on or before October 23, 2026. The meeting will be conducted via Video Conferencing (VC)/ Other Audio Visual Means (OAVM).

Hikal Ltd announced the appointment of Mr. Sameer Hiremath as Chairman and Managing Director (CMD) for a term of five years, effective October 1, 2026, to September 30, 2031. This appointment is subject to shareholder approval at the upcoming Annual General Meeting. Mr. Hiremath, currently Vice Chairman and Managing Director, brings nearly three decades of experience and deep institutional knowledge to the role. He holds degrees in Petrochemical Engineering, an MBA, and an MS in Information Technology from Boston University. The board meeting where this was approved commenced at 11:30 a.m. and concluded at 1:12 p.m. on August 26, 2026.

Hikal Ltd. reported its unaudited financial results for the quarter ended June 30, 2026. Revenue stood at ₹403 Crores, a 6.2% increase year-on-year, despite geopolitical and macroeconomic headwinds. EBITDA margin expanded by 260 basis points year-on-year to 9.2%, with quarterly EBITDA growing 47.4% YoY to ₹37 Crores. The Pharmaceutical business showed recovery, contributing 58% of revenue with ₹233 Crores, driven by improving customer offtake and regulated market demand. The Crop Protection business faced margin pressure due to higher input costs and customer inventory adjustments, though Own Products saw volume-led growth. The company expects business momentum to strengthen progressively through FY27.